Physiologic and pathophysiologic effects of natriuretic peptides and their implications in cardiopulmonary disease

Journal of the American Veterinary Medical Association

Volumn 216, Issue 12, 2000, Pages 1970-1976

  Turk, James R ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NATRIURETIC FACTOR;

CARDIOVASCULAR DISEASE; CORONARY RISK; NONHUMAN; REVIEW; UNITED STATES; VETERINARY MEDICINE;

EID: 0034659257     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.2000.216.1970     Document Type: Review

References (80)

1. Forssmann WG, Richter R, Meyer M. The endocrine heart and natriuretic peptides: histochemistry, cell biology, and functional aspects of the renal urodilatin system. Histochem Cell Biol 1998;110:335-357.
2. Chen HH, Burnett JC Jr. C-type natriuretic peptide: the endothelial component of the natriuretic peptide system. J Cardiovasc Pharmacol 1998;32(suppl 3):S22-S28.
3. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321-328.
4. Aitken GD, Raizis AM, Yandle TG, et al. The characterization of ovine genes for atrial, brain, and C-type natriuretic peptides. Domest Anim Endocrinol 1999;16:115-121.
5. Angus RM, Millar EA, Chalmers GW, et al. Effect of inhaled thiorphan, a neutral endopeptidase inhibitor, on the bronchodilator response to inhaled atrial natriurelic peptide (ANP). Thorax 1996;51:71-74.
6. Vikstrom KL, Bohlmeyer T, Factor SM, et al. Hypertrophy, pathology, and molecular markers of cardiac pathogenesis. Circ Res 1998;20:773-778.
7. Hasegawa K, Fujiwara H, Doyama K, et al. Ventricular expression of atrial and brain natriuretic peptides in dilated cardiomyopathy. An immunohistochemical study of the endomyocardial biopsy specimens using specific monoclonal antibodies. Am J Pathol 1993;142:104-116.
8. Takemura N, Koyama H, Sako T, et al. Bovine atrial natriuretic peptide in heart failure. J Endocrinol 1990;124:463-467.
9. Luchner A, Stevens TL, Borgeson DD, et al. Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998;274:H1684-H1689.
10. Cerra MC. Cardiac distribution of the binding sites for natriuretic peptides in vertebrates. Cardioscience 1994;5:215-224.
11. Borgeson DD, Stevens TL, Heublein DM, et al. Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: functional cardiorenal responses to receptor antagonism. Clin Sci 1998;95:195-202.
12. Ruskoaho H, Leskinen H, Magga J, et al. Mechanisms of mechanical load-induced atrial natriuretic peptide secretion: role of endothelin, nitric oxide and angiotensin II. J Mol Med 1997;75: 876-885.
13. Soualmia H, Barthelemy C, Masson F, et al. Angiotensin II-induced phosphoinositide production and atrial natriuretic peptide release in rat atrial tissue. J Cardiovasc Pharmacol 1997;29: 605-611.
14. Thibault G, Amiri F, Garcia R. Regulation of natriuretic peptide secretion by the heart. Annu Rev Physiol 1999;61:193-217.
15. Perhonen M, Takala TE, Vuolteenaho O, et al. Induction of cardiac natriuretic peptide gene expression in rats trained in hypobaric hypoxic conditions. Am J Physiol 1997;273:R344-R352.
16. Harada M, Itoh H, Nakagawa O, et al. Significance of ventricular myocytes and nonmyocytes interaction during cardiocyte hypertrophy: evidence for endothelin-1 as a paracrine hypertrophic factor from cardiac nonmyocytes. Circulation 1997;96:3737-3744.
17. Baertschi AJ, Jiao JH, Carlson DE, et al. Neural control of ANF release in hypoxia and pulmonary hypertension. Am J Physiol 1990;259:H735-H744.
18. Eble DM, Cadre BM, Zi M, et al. Contractile activity modulates atrial natriuretic factor gene expression in neonatal rat ventricular myocytes. J Mol Cell Cardiol 1998;30:55-60.
19. Chrisman TD, Garbers DL. Reciprocal antagonism coordinates C-type natriuretic peptide and mitogen-signaling pathways in fibroblasts. J Biol Chem 1999;274:4293-4299.
20. Nazario B, Hu RM, Pedram A, et al. Atrial and brain natriuretic peptides stimulate the production and secretion of C-type natriuretic peptide from bovine aortic endothelial cells. J Clin Invest 1995;95:1151-1157.
21. Ogawa Y, Itoh H, Nakao K. Molecular biology and biochemistry of natriuretic peptide family. Clin Exp Pharmacol Physiol 1995;22:49-53.
22. Komatsu Y, Itoh H, Suga S, et al. Regulation of endothelial production of C-type natriuretic peptide in coculture with vascular smooth muscle cells. Role of the vascular natriuretic peptide system in vascular growth inhibition. Circ Res 1996;78:606-614.
23. Beaulieu P, Cardinal R, Page P, et al. Positive chronotropic and inotropic effects of C-type natriuretic peptide in dogs. Am J Physiol 1997;273:H1933-H1940.
24. Schulz S, Waldman SA. The guanylyl cyclase family of natriuretic peptide receptors. Vitam Horm 1999;57:123-151.
25. Kourie JI, Rive MJ. Role of natriuretic peptides in ion transport mechanisms. Med Res Rev 1999;19:75-94.
26. Sabine B, Willenbrock R, Haase H, et al. Cyclic GMP-mediated phospholamban phosphorylation in intact cardiomyocytes. Biochem Biophys Res Commun 1995;214:75-80.
27. McLay JS, Chatterjee PK, Jardine AG, et al. Atrial natriuretic factor modulates nitric oxide production: an ANF-C receptor mediated effect. J Hypertens 1995;13:625-630.
28. Charles CJ, Espiner EA, Richards AM, et al. Comparative bioactivity of atrial, brain, and C-type natriuretic peptides in conscious sheep. Am J Physiol 1996;270:R1324-R1331.
29. Charles CJ, Espiner EA, Nicholls MG, et al. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol 1996;271:R373-R380.
30. Ozaki J, Shimizu H, Hashimoto Y, et al. Enzymatic inactivation of major circulating forms of atrial and brain natriuretic peptides. Eur J Pharmacol 1999;370:307-312.
31. Ando S, Rahman MA, Butler GC, et al. Comparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelin. Hypertension 1995;26:1160-1166.
32. Ferro CJ, Spratt JC, Haynes WG, et al. Inhibition of neutral endopeptidase causes vasoconstriction in human resistance vessels in vivo. Circulation 1998;97:2323-2330.
33. Ohbayashi H, Yamaki K, Suzuki R, et al. Neutral endopeptidase 3.4.24.11 inhibition potentiates the inhibitory effects of type-C natriuretic peptide on leukotriene D4-induced airway changes. Clin Exp Pharmacol Physiol 1998;25:986-991.
34. Yamamoto K, Burnett JC Jr, Redfield MM. Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. Am J Physiol 1997;273:H2406-H2414.
35. Zhang PL, Jimenez W, Mackenzie HS, et al. HS-142-1, a potent antagonist of natriuretic peptides in vitro and in vivo. J Am Soc Nephrol 1994;5:1099-1105.
36. Banks M, Wei CM, Kim CH, et al. Mechanism of relaxations to C-type natriuretic peptide in veins. Am J Physiol 1996;271: H1907-H1911.
37. Hirose M, Furukawa Y, Miyashita Y, et al. CNP causes receptor-mediated positive dromotropic effects in anesthetized dogs hearts. Am J Physiol 1998;275:H717-H720.
38. Brandt RR, Redfield MM, Aarhus LL, et al. Clearance-receptor mediated control of atrial natriuretic factor in experimental congestive heart failure. Am J Physiol 1994;266:R936-R943.
39. Redondo J, Bishop JE, Wilkins MR. Effect of atrial natriuretic peptide and cyclic GMP phosphodiesterase on collagen synthesis by adult cardiac fibroblasls. Br J Pharmacol 1998;124: 1455-1462.
40. Stewart JM, Dean R, Brown M, et al. Bilateral atrial appendectomy abolishes increased plasma atrial natriuretic peptide release and blunts sodium and water excretion during volume loading in conscious dogs. Circ Res 1992;724-732.
41. Vollmar AM, Montag C, Preusser U, et al. Atrial natriuretic peptide and plasma volume of dogs suffering from heart failure or dehydration. Zentralbl Veterinarmed A 1994;41:548-557.
42. Beliveau L, Peronnet F, Bichet DG, et al. Atrial natriuretic peptide release from the ventricles in response to exercise in dogs with atrioventricular block. Can J Physiol Pharmacol 1994;72: 146-151.
43. Nyman S, Kokkonen UM, Dahlborn K. Changes in plasma atrial natriuretic peptide concentration in exercising horses in relation to hydration status and exercise intensity. Am J Vet Res 1998;59:489-494.
44. Woods RL, Jones MJ. Atrial, B-type, and C-type natriuretic peptides cause mesenteric vasoconstriction in conscious dogs. Am J Physiol 1999;276:R1443-R1452.
45. Cavero PG, Margulies KB, Winaver J, et al. Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. Circulation 1990;82:196-201.
46. Hinchcliff KW, McKeever KH. Fluid administration attenuates the haemodynamic effect of furosemide in running horses. Equine Vet J 1998;30:246-250.
47. Sarcevic B, Brookes V, Martin TJ, et al. Atrial natriuretic peptide-dependent phosphorylation of smooth muscle cell particular fraction proteins is mediated by cGMP-dependent protein kinase. J Biol Chem 1989;264:20648-20654.
48. Kohno M, Horio T, Yokokawa K, et al. C-type natriuretic peptide inhibits thrombin- and angiotensin II-stimulated endothelin release via cyclic guanosine 3′,5′-monophosphate. Hypertension 1992;19:320-325.
49. Barbee RW, Perry BD, Ré RN, et al. Hemodynamics in transgenic mice with overexpression of atrial natriuretic factor. Circ Res 1994;74:747-751.
50. Ogawa Y, Itoh H, Tamura N, et al. Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpresses the brain natriuretic peptide gene. J Clin Invest 1994;93:1911-1921
51. Melo LG, Veress AT, Ackermann U, et al. Chronic hypertension in ANP knockout mice: contribution of peripheral resistance. Regul Pept 1999;79:109-115.
52. Kleinhart HD, Volpe M, Odell G, et al. Cardiovascular effects of atrial natriuretic factor in anesthetized and conscious dogs. Hypertension 1986;8:312-316.
53. Seymour AA, Asaad MM, Sheldon JH, et al. Atrial natriuretic peptide in chronically hypertensive dogs. Hypertension 1995;26:634-641.
54. Nagaya N, Nishikimi T, Uematsu M, et al. Secretion patterns of brain natriuretic peptide and atrial natriuretic peptide in patients with or without pulmonary hypertension complicating atrial septal defect. Am Heart J 1998;136:297-301.
55. Rascher W, Seyberth HW. Atrial natriuretic peptide and patent ductus arteriosus in preterm infants. Arch Dis Child 1987;62:1165-1167.
56. Asano K, Kadosawa T, Okumura M, et al. Peri-operative changes in echocardiographic measurements and plasma atrial and brain natriuretic peptide concentrations in 3 dogs with patent ductus arteriosus. J Vet Med Sci 1999;61:89-91.
57. Colbatzky F, Vollman A, Monch U, et al. Synthesis and distribution of atrial natriuretic peptide (ANP) in hearts from normal dogs and those with cardiac abnormalities. J Comp Pathol 1993;108:149-163.
58. Charles CJ, Kaaja RJ, Espiner EA, et al. Natriuretic peptides in sheep with pressure overload left ventricular hypertrophy. Clin Exp Hypertens 1996;18:1051-1071.
59. Willenbrock R, Scheuermann M, Hohnel K, et al. Acute and chronic neutral endopeptidase inhibition in rats with aortocaval shunt. Hypertension 1996;27:1259-1266.
60. Haggstrom J, Hansson K, Kvart C, et al. Effects of naturally acquired decompensated mitral valve regurgitation on the reninangiotensin-aldosterone system and atrial natriuretic peptide concentration in dogs. Am J Vet Res 1997;58:77-82.
61. Rademaker MT, Charles CJ, Espiner EA, et al. Neutral endopeptidase inhibition: augmented atrial and brain natriuretic peptide, haemodynamic and natriuretic responses in ovine heart failure. Clin Sci (Colch) 1996;91:283-291.
62. Wada A, Tsutamato T, Maeda Y, et al. Endogenous atrial natriuretic peptide inhibits endothelin-1 secretion in dogs with severe congestive heart failure. Am J Physiol 1996;270:H819-H824.
63. Margulies KB, Barclay PL, Burnett JC Jr. The role of neutral endopeptidase in dogs with evolving congestive heart failure. Circulation 1995;91:2036-2042.
64. Legault L, Cernacek P, Levy M, et al. Renal tubular responsiveness to atrial natriuretic peptide in sodium-retaining chronic caval dogs. A possible role for kinins and luminal actions of the peptide. J Clin Invest 1992;90:1425-1435.
65. Yoneda H, Yamada H, Yano K, et al. Blunted natriuretic response to endogenous atrial natriuretic peptide during rapid cardiac pacing in anaesthetized dogs. Clin Exp Pharmacol Physiol 1998;25:341-346.
66. Mallery KF, Freeman LM, Harpster NK, et al. Factors contributing to the decision for euthanasia of dogs with congestive heart failure. J Am Vet Med Assoc 1999;214:1201-1204.
67. Paulus WJ. Paracrine coronary endothelial modulation of diastolic left ventricular function in man: implications for diastolic heart failure. J Card Fail 1996;2(suppl 4):S155-S164.
68. Chu A, Stakely A, Lin CC, et al. Effects of atrial natriuretic peptide on transmural blood flow and reactive hyperemia in the presence of flow-limiting coronary stenosis in the awake dog: evidence for dilation of the intramural vasculature. Circ Res 1989;64:600-606.
69. Zellner C, Protter AA, Ko E, et al. Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries. Am J Physiol 1999;276:H1049-H1057.
70. Yu CM, Sanderson JE, Shum IO, et al. Diastolic dysfunction and natriuretic peptides in systolic heart failure. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J 1996;17:1694-1702.
71. Fujisaki H, Ito H, Hirata Y, et al. Natriuretic peptides inhibit angiotensin II-induced proliferation of rat cardiac fibroblasts by blocking endothelin-1 gene expression. J Clin Invest 1995;96:1059-1065.
72. Calderone A, Thaik CM, Takahashi N, et al. Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 1998;101:812-818.
73. Marie C, Mossiat C, Gros C, et al. Effect of prolonged inhibition of neutral endopeptidase on cardiac hypertrophy in rats with myocardial infarction. Cardiovasc Drugs Ther 1996;10:593-598.
74. Morice AH, Pepke-Zaba J, Brown MJ, et al. Atrial natriuretic peptide in primary pulmonary hypertension. Eur Respir J 1990;3:910-913.
75. Klinger JR, Warburton RR, Pietras LA. et al. Genetic disruption of atrial natriuretic peptide causes pulmonary hypertension in normoxic and hypoxic mice. Am J Physiol 1999;276: L868-L874.
76. Vachiery JL, Lejeune P, Hallemans R, et al. Atrial natriuretic peptides in canine hypoxic pulmonary vasoconstriction. Cardiovasc Res 1990;24:352-357.
77. Eddahibi S, Raffestin B, Le Monnier de Gouville AC, et al. Effect of DMPPO, a phosphodiesterase type 5 inhibitor, on hypoxic pulmonary hypertension in rats. Br J Pharmacol 1998;125:681-688.
78. Skwarski KM, Morrison D, Barratt A, et al. Effects of hypoxia on renal hormonal balance in normal subjects and in patients with COPD. Respir Med 1998;92:1331-1336.
79. Marr KA, Lees P, Page CP, et al. Inhaled leukotrienes cause bronchoconstriction and neutrophil accumulation in horses. Res Vet Sci 1998;64:219-224.
80. van der Velden VHJ, Naber BAE, vad der Spoel P, et al. Cytokines and glucocorticoids modulate human bronchial epithelial cell peptidases. Cytokine 1998;10:55-65.